HNRNPK and neoplasm: Therefore, the lncRNA–LBCS/hnRNPK–EZH2/SOX2 regulatory axis acts as a tumor suppressor in bladder tumorigenesis and progression, and could be considered as a therapeutic target for clinical intervention in chemoresistant bladder cancer.